Merck Sharp + Dohme B.v.

Msd Oss B.v.

Meck Sharp & Dohme B.v.

Intervet International B.v.

Harm Veenstra

Wouter De Graaff

Titia Martine Truce Mulders

Fabrice Payot

Marc-Antoine Driancourt

Titia Mulders

Laura Buttafoco

René Voss

The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.

X-ray visible drug delivery device

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.

Intrauterine system

An intrauterine system () for the retention of a biologically active compound within the uterus of a female mammal is formed by a frame () defining an interior space () for receipt of a deposit of the compound (). The frame has an open structure () allowing access to a substantial part of an outer surface of the deposit and the deposit has a rate controlling structure that controls a rate of release of the compound within the Uterus. Retention elements () are provided on the frame for retaining the frame within the uterus.

Intrauterine deposit

Growing community of inventors

Oss, Netherlands

Harm Veenstra